2. Disease Areas
  3. Cancer Respiratory Disease
  4. Lung Cancer Respiratory Cancer
  5. Small Cell Lung Cancer

Small Cell Lung Cancer

Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by rapid tumor growth, a high proliferation rate, and early widespread metastasis. It is classified into two stages: limited disease (LD-SCLC), confined to one side of the chest and regional lymph nodes, and extensive disease (ED-SCLC), involving distant sites beyond one hemithorax. Treatment strategies focus on systemic therapies due to the disease's rapid progression, with chemotherapy and radiation forming the backbone of initial management. Immunotherapy has emerged as a promising addition in frontline treatment, particularly for ED-SCLC, while ongoing research aims to identify targeted therapies based on the molecular and biological features of SCLC, especially to address the poor prognosis and limited options in relapsed or refractory cases.

Small Cell Lung Cancer (1):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10585S1
    Valproic acid-d6 87745-18-4 99.83%
    Valproic acid-d6 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
    Valproic acid-d<sub>6</sub>